Morningstar's Matt Coffina looks back on some recent missed opportunities and what he learned from them--also, a couple of stocks he's glad he avoided.
With dividend yields below long-run historical norms and the market overall looking pricey, growth in companies' intrinsic values will be key for stock investors, says Morningstar's Matt Coffina.
StockInvestor editor Paul Larson discusses the importance of investing in companies that can compound their intrinsic values, buying on the cheap, avoiding stop-loss orders, and more.
The financial crisis proved that tumultuous events can and do happen, and investors need to keep a long-term perspective in a market that is incredibly short-term focused, says StockInvestor editor Paul Larson .
StockInvestor editor Paul Larson details recent changes to Morningstar's Wide Moat Focus Index, noting how the rally in wide-moat names could have them more fairly priced than lower-quality stocks.
Tax advantages and economic moats allow master limited partnerships to offer investors much more than just high yields, says Morningstar's Paul Larson .
Competitive advantages improved for one health-care firm, while a spin-off at another narrowed its moat, says Morningstar's Paul Larson in his discussion on recent moat-rating upgrades and downgrades.
Recent decelerating revenue growth has disappointed investors but is a temporary phenomenon, says Morningstar StockInvestor editor Matt Coffina.
Investors concerned with Express Scripts' integration of Medco are overlooking the firm's long-term potential to benefit from an increased focus on health-care cost-cutting, says Morningstar StockInvestor editor Matt Coffina.
Although a drawdown in the short term is a real possibility, investors should still see a 4.5% to 6% real return over the long run, says Morningstar's Matt Coffina.